nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A machine learning-based method for feature reduction of methylation data for the classification of cancer tissue origin
|
De Velasco, Marco A. |
|
|
29 |
12 |
p. 1795-1810 |
artikel |
2 |
Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor
|
Nakatsukasa, Hitomi |
|
|
29 |
12 |
p. 1840-1849 |
artikel |
3 |
Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan
|
Yoshimura, Akihiro |
|
|
29 |
12 |
p. 1916-1924 |
artikel |
4 |
Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer
|
Inada, Hiroki |
|
|
29 |
12 |
p. 1908-1915 |
artikel |
5 |
Conversion surgery for esophageal and esophagogastric junction cancer
|
Shoji, Yoshiaki |
|
|
29 |
12 |
p. 1777-1784 |
artikel |
6 |
Diagnostic performance of TILs–US score and LPBC in biopsy specimens for predicting pathological complete response in patients with breast cancer
|
Shigematsu, Hideo |
|
|
29 |
12 |
p. 1860-1869 |
artikel |
7 |
Efficacy and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: a preliminary report of real-world data from a single institution
|
Yasuda, Yosuke |
|
|
29 |
12 |
p. 1925-1930 |
artikel |
8 |
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology
|
Nakashima, Kazuhisa |
|
|
29 |
12 |
p. 1785-1794 |
artikel |
9 |
Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan
|
Hara, Takuto |
|
|
29 |
12 |
p. 1931-1936 |
artikel |
10 |
First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048
|
Oridate, Nobuhiko |
|
|
29 |
12 |
p. 1825-1839 |
artikel |
11 |
Fourteen-year follow-up results of imatinib therapy in patients with unresectable and metastatic gastrointestinal stromal tumors
|
Kanda, Tatsuo |
|
|
29 |
12 |
p. 1870-1877 |
artikel |
12 |
Genomic landscape of cutaneous, acral, mucosal, and uveal melanoma in Japan: analysis of clinical comprehensive genomic profiling data
|
Hida, Tokimasa |
|
|
29 |
12 |
p. 1984-1998 |
artikel |
13 |
Lateral node metastasis in low rectal cancer as a hallmark to predict recurrence patterns
|
Shinto, Eiji |
|
|
29 |
12 |
p. 1896-1907 |
artikel |
14 |
List of reviewers 2023–2024
|
|
|
|
29 |
12 |
p. 1999-2002 |
artikel |
15 |
Local extension findings on MRI compensate for the ability of pathological staging to predict oncological outcome
|
Wakamiya, Takahito |
|
|
29 |
12 |
p. 1811-1816 |
artikel |
16 |
Molecular profiling of risk factors for relapse in Japanese patients with stage II colorectal cancer: a retrospective cohort study
|
Kasai, Shunsuke |
|
|
29 |
12 |
p. 1887-1895 |
artikel |
17 |
Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer
|
Mitsuyoshi, Ayumu |
|
|
29 |
12 |
p. 1850-1859 |
artikel |
18 |
Out-of-pocket fertility preservation expenses: data from a Japanese nationwide multicenter survey
|
Ono, Masanori |
|
|
29 |
12 |
p. 1959-1966 |
artikel |
19 |
Pembrolizumab in Japanese patients with primary mediastinal large B-cell lymphoma: results from the KEYNOTE-A33 study
|
Kato, Koji |
|
|
29 |
12 |
p. 1977-1983 |
artikel |
20 |
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of sacituzumab govitecan for breast cancer, fruquintinib for colorectal cancer, amivantamab for lung cancer, repotrectinib for lung cancer, tasurgratinib for biliary tract cancer, enfortumab vedotin plus pembrolizumab for urothelial cancer, and dabrafenib plus trametinib for glioma in Japan
|
Matsumura, Noriomi |
|
|
29 |
12 |
p. 1775-1776 |
artikel |
21 |
Real-world application of comprehensive genomic profiling for gynecological malignancies: a multicenter observational study
|
Fukuda, Mayu |
|
|
29 |
12 |
p. 1967-1976 |
artikel |
22 |
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor
|
Yamamoto, Yutaka |
|
|
29 |
12 |
p. 1946-1958 |
artikel |
23 |
Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study
|
Yamamoto, Yoshiyuki |
|
|
29 |
12 |
p. 1878-1886 |
artikel |
24 |
Relationship between magnesium dosage and the preventive effect on cisplatin-induced nephrotoxicity: meta-analysis and meta-regression analysis
|
Okamoto, Keisuke |
|
|
29 |
12 |
p. 1817-1824 |
artikel |
25 |
Reproductive organ involvement in women undergoing radical cystectomy for urothelial bladder cancer: a nationwide multicenter study
|
Kato, Minoru |
|
|
29 |
12 |
p. 1937-1945 |
artikel |